Speed
44 days to first decision for reviewed manuscripts only
38 days to first decision for all manuscripts
100 days from submission to acceptance 
21 days from acceptance to publication

Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed journal that publishes on all aspects of tumor immunology and cancer immunotherapy, aiming to enrich communication and advance scientific understanding in this rapidly evolving field. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity. 

Case report
Clinical trials monitor
Commentary
Hypothesis
Meeting report
Position article and guidelines
Research article
Review
Short report

Editor-in-Chief 
Prof Pedro Romero, Ludwig Center for Cancer Research, Switzerland
Section Editors
Basic tumor immunology
Prof Cornelis JM Melief, ISA Therapeutics BV, Netherlands 
Case reports 
Prof Alfred Zippelius, University Hospital Basel, Switzerland
Clinical trials monitor 
Dr Leisha A Emens, Johns Hopkins University, USA
Clinical/translational cancer immunotherapy 
Dr James L Gulley, National Cancer Institute, National Institutes of Health, USA
Dr Douglas G McNeel, University of Wisconsin Carbone Cancer Center, USA
Commentary/editorials 
Dr Christian Capitini, University of Wisconsin Madison, USA
Guidelines and Consensus Statements 
Dr Robert L Ferris, University of Pittsburgh, USA
Immunotherapy biomarkers 
Dr Ignacio Melero, University of Navarra, USA
Reviews 
Dr Sandra Demaria, Weill Cornell Medical College, USA
Prof Thomas F Gajewski, University of Chicago, USA
Deputy Editors
Basic tumor immunology
Sjoerd H van der Burg, Leiden University Medical Center, Netherlands
Immunotherapy biomarkers
Kurt A Schalper, Yale School of Medicine, United States
Clinical/translational cancer immunotherapy
Claudia Palena, National Institutes of Health, United States
Associate Editors
Basic tumor immunology
Dr Scott I Abrams, Roswell Park Cancer Institute, USA
Prof Paul A Antony, University of Maryland, USA
Dr Timothy NJ Bullock, University of Virginia, USA
Prof Gennaro Ciliberto, IRCCS Istituto Nazionale Tumori, Italy 
Dr Jonathan L. Curry, MD Anderson Cancer Center, USA
Dr Madhav V Dhodapkar, Yale University, USA
Dr Norman M Greenberg, Atreca, USA
Dr Arthur A Hurwitz, Agenus, USA
Dr Masahisa Jinushi, Merck & Co., Inc., Japan 
Prof Khashayarsha Khazaie, Northwestern University, USA
Dr Michelle Krogsgaard, New York University, USA
Dr Maria Rescigno, European Institute of Oncology, Italy
Dr Lillian Seu, Allogene Therapeutics, USA 
Dr Sjoerd H Van der Burg, Leiden University Medical Center, Netherlands 
Dr Andrew D Weinberg, Earle A. Chiles Research Institute, USA
Case reports
Dr Jack Bui, University of California San Diego, USA
Dr Richard D. Carvajal, Columbia University Medical Center, USA
Dr Matthew Hellmann, Memorial Sloan Kettering Cancer Center, USA
Dr Heinz Laubli, University Hospital Basel, Switzerland
Dr Steven H Lin, University of Texas MD Anderson Cancer Center, USA
Prof Sebastian Kobold, Ludwig Maximilians University of Munich, Germany
Prof Andreas Mackensen, University Hospital Erlangen, Germany
Dr Olivier Michielin, University of Lausanne, Switzerland
Dr Hiroyoshi Nishikawa, National Cancer Center, Japan
Dr Max Topp, University of Würzburg, Germany
Dr Michael von Bergwelt-Baildon, University of Cologne, Germany
Dr Geoffrey R. Weiss, University of Virginia, USA
Dr Hassane Zarour, University of Pittsburgh, USA
Clinical trials monitor
Dr Stephen Ansell, Mayo Clinic, USA
Dr Jonathan Cebon, Ludwig Institute for Cancer Research, Australia
Dr Tai-Tsang Chen, Columbia University; BMS, USA
Dr Jolanda de Vries, Radboud University Nijmegen, Netherlands
Dr Silvia Formenti, Weill Cornell Medical College, USA
Dr Howard Kaufman, Rutgers Cancer Institute of New Jersey, USA
Dr Larry Kwak, City of Hope, USA
Dr Sherene Loi, Peter MacCallum Cancer Centre, Australia
Dr Kunle Odunsi, Roswell Park Cancer Institute, USA
Dr Michael Postow, Memorial Sloan-Kettering Cancer Center, USA
Prof Peter Schmid, Imperial College London, United Kingdom
Dr Hiroshi Shiku, Mie University Graduate School of Medicine, Japan
Dr Daniel Speiser, Ludwig Institute for Cancer Research, Switzerland
Dr Louis Weiner, Georgetown University Lombardi Cancer Center, USA
Dr Yi-Long Wu, Guangdong General Hospital and Academy of Medical Sciences, China
Dr Xiabo Ye, Johns Hopkins University School of Medicine, USA
Clinical/translational cancer immunotherapy
Dr Paolo A Ascierto, Istituto Nazionale Tumori Fondazione G. Pascale, Italy 
Dr Ernest C Borden, The Cleveland Clinic Foundation, USA
Dr Lisa Butterfield, Parker Institute for Cancer Immunotherapy, USA
Dr Lawrence Fong, University of California, San Francisco, USA
Dr Nancy M Hardy, University of Maryland, USA
Dr Christian S Hinrichs, National Cancer Institute, ETIB, USA
Dr Pawel Kalinski, Roswell Park Comprehensive Cancer Institute, USA
Dr Yutaka Kawakami, Keio University School of Medicine, Japan 
Dr Beatrix Kotlan, National Institute of Oncology, Hungary  
Dr Dung Le, Johns Hopkins University, USA
Prof Alessandro Lugli, University of Bern, Switzerland 
Dr Michele Maio, University Hospital of Siena, Italy 
Dr Ravi A Madan, National Cancer Institute, National Institutes of Health, USA
Prof Giorgio Parmiani, Fondazione C.S. Raffaele Del Monte Tabor, Italy 
Dr Anna C Pavlick, NYU Cancer Institute, USA
Dr Padmanee Sharma, MD Anderson Cancer Center, USA
Dr Jeffrey S Weber, NYU Langone Medical Center, USA
Dr Cassian Yee, MD Anderson Cancer Center, USA
Commentary/editorials
Dr Ana Anderson, Harvard University, USA
Prof Wolf-Hervé Fridman, Cordeliers Research Center, France 
Prof Bryon D Johnson, Medical College of Wisconsin, USA
Dr William J Murphy, University of California, Davis, USA
Dr Gabriel Rabinovich, Instituto de Biologia y Medicina Experimental, Argentina 
Dr William L Redmond, Earle A. Chiles Research Institute, USA
Prof Paul M Sondel, University of Wisconsin, USA
Guidelines and consensus statements
Prof Paulo A. Ascierto, Istituto Nazional Tumori-Fondazione 'G.Pascale', Italy
Dr Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, USA
Dr Michael R. Bishop, University of Chicago, USA
Prof Michael Platten, Ruprecht-Karls University Heidelberg, Germany
Immunotherapy biomarkers
Dr Luigi Buonaguro, Instituto Nazionale Tumori, IRCCs, Fondazione Pascale Napoli, Italy
Dr Alessandra Cesano, Nanostring, Inc., USA
Dr Alexandra Snyder Charen, Merck and Dohme Corp, USA
Dr Priti Hegde, Genentech, USA
Dr Michael Kalos, Janssen Oncology, USA
Dr Thomas Kleen, Precision for Medicine, Germany 
Dr Rejean Lapointe, Universite De Montreal, University Hospital (CRCHUM), Canada 
Dr Christian H Ottensmeier, University of Southampton, UK
Dr Licia Rivoltini, Fondazione IRCCS Istituto Nazionale Tumori, Italy 
Dr Kimberly A Shafer-Weaver, Merck & Co., USA
Dr Kurt A Schalper, Yale School of Medicine, USA
Dr Craig L Slingluff, University of Virginia, USA
Dr Ena Wang, Allogene Therapeutics, USA
Dr Jianda Yuan, Merck & Co., USA
Reviews
Dr Michael B Atkins, Georgetown-Lombardi Comprehensive Care Center, USA
Dr Ira Mellman, Genentech, USA
Dr James J Mule, H. Lee Moffitt Comprehensive Cancer Center, USA